NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Vericel Corporation (VCEL) Stock Analysis

Vericel Corporation (VCEL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VCEL

$40.94

+$0.36 (+0.89%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VCEL with… →

VCEL Key Statistics

As of Oct 21, 2026
Trading
Open
$40.00
Previous Close
$40.58
Day's Range
40.00–41.04
52-Week Range
28.95–49.32
Volume
432.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.03
Valuation
Market Cap
$2.10B
P/E Ratio
87.11
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
48.39
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.84
EPS (ttm)Profit attributable to each share over the last twelve months.
0.47
Financials (FY)
Revenue (FY)
$276.26M+16.45%
Net Income (FY)
$16.52M+59.41%
Profit marginThe share of revenue left as profit after all costs and taxes.
7.91%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.21M
1-Year Return
+12.32%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
509.54K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VCEL closed at $40.94, +12.32% over 1 year.

Vericel Corporation (VCEL) has a market capitalization of $2.10B.

In fiscal 2025, VCEL reported revenue of $276.26M.

VCEL Stock Return by Calendar Year

Vericel Corporation (VCEL) 10-year return: what $10,000 became

1 year
$10,000 $11,232
+12.32%
5 years
$10,000 $8,096
−19.04%
10 years
$10,000 $167,102
+1,571.02%

If you had invested $10,000 in Vericel Corporation (VCEL) 10 years ago, at the close on October 21, 2016, it would have been worth $167,102 at the close on October 21, 2026: +1,571.02% in total, +32.53% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+13.69%
2025−34.42%
2024+54.20%
2023+35.19%
2022−32.98%
2021+27.27%
2020+77.47%
2019+0.00%
2018+219.27%
2017+81.67%
2016 (partial year)+31.58%

As of October 21, 2026.

VCEL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$276.26M$16.52M6.0%
2024$237.22M$10.36M4.4%
2023$197.52M−$3.18M−1.6%
2022$164.37M−$16.71M−10.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$276.26M$205.60M$11.04M$16.52M6.0%
2024$237.22M$172.11M$4.52M$10.36M4.4%
2023$197.52M$135.58M−$6.46M−$3.18M−1.6%
2022$164.37M$109.79M−$17.06M−$16.71M−10.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VCEL Valuation vs Biotechnology Median

Median of 608 stocks
MetricVCELBiotechnology medianvs median
P/E87.1116.605.2x the median
P/S ratio6.8413.3049% below
Profit margin7.91%−38.31%46.2 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Vericel Corporation (VCEL) is capitalised at $2.10B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 398.

Over the past 52 weeks the price has ranged from $28.95 to $49.32. VCEL last closed at $40.94 on October 21, 2026. That is +$0.36 (+0.89%) against the previous close. The latest close sits 41.42% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $276.26M. That is +16.45% against the prior fiscal year, when revenue was $237.22M. The same year closed with net income of $16.52M. That is +59.41% against the prior fiscal year. The reported profit margin is 7.91%. That is 46.2 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 0.47.

Across the 4 fiscal years on file, revenue moves from $164.37M in 2022 to $276.26M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

VCEL trades at a trailing price-to-earnings ratio of 87.11. That is 5.2 times the Biotechnology median of 16.6. On forward earnings the ratio is 48.39. The price-to-sales ratio is 6.84. On price-to-sales that is 48.53% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +12.32%. Measured over 10 years, that is +32.53% a year compounded. The reported beta is 1.03. Annualized volatility over the trailing 10 years is 62.45%.

Growth & Income

The record shows no dividend for VCEL.

The strongest complete calendar year on file is 2018 at +219.27%; the weakest is 2025 at −34.42%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the total return is +13.69% year to date.

Peer Comparison

Vericel Corporation (VCEL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vericel Corporation VCEL $2.10B 87.1
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Vericel Corporation trades at a P/E of 87.1.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Visit website →